RESUMEN

Birthplace, as a proxy for environmental exposures (e.g., diet), may influence metabolomic profiles and influence risk of cancer. This secondary analysis investigated metabolomic profile differences between foreign and U.S.-born Mexican-origin (MO) Hispanic men to shed light on potential mechanisms through which foreign- and U.S.-born individuals experience differences in cancer risk and risk factors. Plasma samples from MO Hispanic men (N = 42) who participated in a previous lifestyle intervention were collected pre-and post-intervention. Metabolomic profiles were characterized from samples using ultra performance liquid chromatography-quadrupole time of flight mass spectrometry (UPLC-QTOF). Models were visualized using supervised orthogonal projections to latent structures-discriminant analysis (OPLS-DA). Progenesis QI was used for peak integration and metabolite identification. Plasma metabolomic profiles differed between foreign- and U.S.-born pre-intervention (R2 = .65) and post-intervention (R2 = .62). Metabolomic profiles differed pre- versus post-intervention (R2 = .35 and R2 = .65) for the foreign- and U.S.-born group, respectively. Both endogenous metabolites and dietary components characterized differences between foreign- and U.S.-born participants pre- and post-intervention. Plasma metabolomic profiles from MO Hispanic men differed by birthplace. These results advance our understanding of relevant exposures that may affect cancer risk among MO Hispanic men born abroad or in the United States.

Asunto(s)

RESUMEN

Objective: Undetected diabetes in pregnancy (DiP) can lead to deleterious consequences. Strengthening health systems and implementing national standardized protocols for screening and management can improve outcomes. This study aimed to achieve consensus on clinical guidelines and facilitate universal screening using standardized testing and an app. Design and Methodology: An integrated care model was developed and antenatal caregivers were trained on screening and management of DiP. A secure Information and Communication Technologies (ICT) solution for real-time communication of results was designed and piloted as the reporting system. The app provided automatic alerts to patients and doctors facilitating timely intervention and offered self-management tools. Pregnant women ≥ 18 years, n = 655 at two antenatal clinics in Trinidad (1 public and 1 private hospital) were screened using a standard 75g 2-hour oral glucose tolerance test (OGTT) after an overnight fast. Seven lab technologists and 24 doctors were trained to use the app. Cost-effectiveness was assessed. Results: National consensus was achieved with 197 antenatal caregivers, for universal screening for DiP. The app facilitated a reporting system of blood glucose results and delivered real-time SMS text and e-mail alerts to participants. 10.1% of participants had abnormal fasting glucose and 14.1% had at least one abnormal reading between 0hr to 2hrs. Universal screening for GDM was cost-effective in the local setting. Results: National consensus was achieved with 197 antenatal caregivers, for universal screening for DiP. The app facilitated a reporting system of blood glucose results and delivered real-time SMS text and e-mail alerts to participants. 10.1% of participants had abnormal fasting glucose and 14.1% had at least one abnormal reading between 0hr to 2hrs. Universal screening for GDM was cost-effective in the local setting. Conclusions: The high prevalence of DiP in T&T justifies the need for universal screening and related health systems change. Training healthcare teams in DiP screening and ICT-enabled management are essential elements of a standardized health system which features real-time reporting.

Asunto(s)

RESUMEN

ABSTRACT Objective: To determine the feasibility of recommending a screening process for non-communicable diseases (NCDs) and their risk factors, as a national and regional model. Methods: A cross-sectional, six-station process was carried out. It consisted of invitation and consent, history (personal and family history of NCDs), biometrics (waist circumference and body mass index), blood levels (lipids and glycosylated haemoglobin) and urinalysis (microalbuminuria), basic examinations (blood pressure, peripheral neuropathy, presence of acanthosis nigricans and visual acuity), and an exit interview. Net present value (NPV) calculations were carried out for very high-risk patients (those with a > 30% risk of a cardiovascular event (limb amputation) in the next 10 years) for two discount rates: 0.75% (United States of America) and 3.4% (Trinidad and Tobago). Results: A convenience sample of 514 walk-in patients (56.2% recruitment rate) was screened (about 23 patients per day). The median time for a patient attending all stations was 21 minutes (range: 11-59 minutes). Of the six stations, the laboratory took the longest: median 10 minutes (range: 2-50 minutes). The entire project cost US$20 439 (US$39.76 per patient). Between one and seven very high-risk patients (three sub-groups of patients had this risk profile) were identified. The cost of identifying a very high-risk patient ranged from US$2907 to US$20 349. The NPV of identifying these high-risk patients ranged from -US$6748.71 to US$14 725 and was favourable for three of four monetary scenarios. Conclusion: A six-station process to provide rapid screening of walk-in patients for NCDs was found to be feasible and provided monetary value in three of four scenarios in a Trinidad and Tobago setting.

RESUMEN Objetivo: Determinar la viabilidad de recomendar un proceso de cribado de las enfermedades no transmisibles (ENT) y sus factores de riesgo, como modelo nacional y regional. Métodos: Se realizó un proceso transversal de seis estaciones. El mismo consistió en invitación y consentimiento; historia (antecedentes personales y familiares de ENT); biometría (circunferencia de la cintura e índice de masa corporal); niveles sanguíneos (lípidos y hemoglobina glicosilada); y análisis de orina (microalbuminuria); exámenes básicos (presión arterial, neuropatía periférica, presencia de acantosis nigricans y agudeza visual); y una entrevista de salida. Se realizaron cálculos del valor actual neto (VAN) para pacientes de muy alto riesgo - pacientes con riesgo de un 30% de evento cardiovascular (amputación de extremidades) en los próximos 10 años - para dos tasas de descuento: 0.75% (Estados Unidos de América) y 3.4% (Trinidad y Tobago). Resultados: Una muestra de conveniencia de 514 pacientes ambulatorios (tasa de reclutamiento de 56.2%) fue sometida a pruebas de detección (unos 23 pacientes por día). El tiempo promedio para que un paciente asistiera a todas las estaciones fue de 21 minutos (rango: 11-59 minutos). De las seis estaciones, el laboratorio tomó el tiempo más largo: un promedio de 10 minutos (rango: 2-50 minutos). El proyecto entero costó $20 439 USD (39.76 USD por paciente). Entre uno y siete pacientes de muy alto riesgo (tres subgrupos de pacientes tenían este perfil de riesgo) fueron identificados. El costo de identificar a un paciente de muy alto riesgo osciló entre $2907 USD y $20 349 USD. El VAN de identificación de estos pacientes de alto riesgo fluctuó de $6748.71 a $14 725 USD, y fue favorable para tres de cuatro escenarios monetarios. Conclusión: Se halló que un proceso de seis estaciones para pruebas de detección rápidas de ENT a pacientes ambulatorios, es factible y proporciona valor monetario en tres de cuatro escenarios en un contexto de Trinidad y Tobago.

Asunto(s)